Janux Therapeutics, Inc. Price & Performance (JANX)

Janux Therapeutics shares rose 3.49% to $29.69, with 93% of analysts rating it a buy and a consensus price target of $85.33, suggesting significant upside. Technical indicators remain positive despite recent volatility, and major institutional investors continue to increase their holdings, reflecting ongoing confidence in the company’s cancer immunotherapy pipeline.123

Trading in Janux Therapeutics has seen increased insider and institutional activity, with notable purchases and sales by key stakeholders. The stock, currently trading near $29, is up 10% over two weeks but remains volatile. Analysts forecast continued losses this year, but long-term prospects are bolstered by ongoing clinical trials and a robust cash position.34

Janux Therapeutics was upgraded to a buy candidate following recent gains, although analysts caution about short-term downside risk due to the stock’s high volatility. The share price has fluctuated widely, and while the long-term outlook is optimistic, short-term traders are advised to monitor key support and resistance levels closely.15